The DOI matches its Crossref record; 403 of the 403 references it cites were found in a registry or an index.
Frontiers in the treatment of glioblastoma: Past, present and emerging
Abstract
Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive research over the last several decades, the survival rates for GBM have not improved and prognosis remains poor. To date, only a few therapies are approved for the treatment of GBM with the main reasons being: 1) significant tumour heterogeneity which promotes the selection of resistant subpopulations 2) GBM induced immunosuppression and 3) fortified location of the tumour in the brain which hinders the delivery of therapeutics. Existing therapies for GBM such as radiotherapy, surgery and chemotherapy have been unable to reach the clinical efficacy necessary to prolong patient survival more than a few months. This comprehensive review evaluates the current and emerging therapies including those in clinical trials that may potentially improve both targeted delivery of therapeutics directly to the tumour site and the development of agents that may specifically target GBM. Particular focus has also been given to emerging delivery technologies such as focused ultrasound, cellular delivery systems nanomedicines and immunotherapy. Finally, we discuss the importance of developing novel materials for improved delivery efficacy of nanoparticles and therapeutics to reduce the suffering of GBM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Moghaddam, S. P. H., Mohammadpour, R., & Ghandehari, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.028 · Cited by 120
RetractedAn MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma
Shi, J., Hou, S., Huang, J., Wang, S., Wei, H. J., Huang, C., Liu, X., Jiang, R., Qian, W., Lu, J., et al. (2017) · Nanoscale · doi:10.1039/c6nr08786h · Cited by 38
RetractedRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Introduction to Metal–Organic Frameworks
Zhou, H.-C., Long, J. R., & Yaghi, O. M. (2012) · Chemical Reviews · doi:10.1021/cr300014x · Cited by 7,720
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Ultrahigh Porosity in Metal-Organic Frameworks
Furukawa, H., Ko, N., Go, Y. B., Aratani, N., Choi, S. B., Choi, E., Yazaydin, A. Ö., Snurr, R. Q., O’Keeffe, M., Kim, J., et al. (2010) · Science · doi:10.1126/science.1192160 · Cited by 3,904
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Shape effects of filaments versus spherical particles in flow and drug delivery
Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., & Discher, D. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.70 · Cited by 2,565
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Mesoporous Materials for Drug Delivery
Vallet‐Regí, M., Balas, F., & Arcos, D. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200604488 · Cited by 2,507
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
Role of target geometry in phagocytosis
Champion, J. A., & Mitragotri, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600997103 · Cited by 2,074
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
Ostrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou223 · Cited by 1,718
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Applications of advanced hybrid organic–inorganic nanomaterials: from laboratory to market
Sanchez, C., Belleville, P., Popall, M., & Nicole, L. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00136h · Cited by 1,462
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U. (2017) · PubMed · doi:10.22034/apjcp.2017.18.1.3 · Cited by 1,231
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Glioblastoma: Overview of Disease and Treatment
Davis, M. (2016) · Clinical Journal of Oncology Nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,205
Skjerdal, T., Gefferth, A., Spajic, M., Estanga, E. G., de Cecare, A., Vitali, S., Pasquali, F., Bovo, F., Manfreda, G., Mancusi, R., et al. (2017) · BioMed Research International · doi:10.1155/2017/6353510 · Cited by 1,178
Temozolomide resistance in glioblastoma multiforme
Lee, S. Y. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.007 · Cited by 1,163
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Assumptions in the radiotherapy of glioblastoma
Hochberg, F. H., & Pruitt, A. (1980) · Neurology · doi:10.1212/wnl.30.9.907 · Cited by 992
Size and shape effects in the biodistribution of intravascularly injected particles
Decuzzi, P., Godin, B., Tanaka, T., Lee, S.-Y., Chiappini, C., Liu, X., & Ferrari, M. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.014 · Cited by 965
Mesoporous Silica Nanoparticles for Drug Delivery
Manzano, M., & Vallet‐Regí, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201902634 · Cited by 939
Murdoch, C., Giannoudis, A., & Lewis, C. E. (2004) · Blood · doi:10.1182/blood-2004-03-1109 · Cited by 915
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study
Rastinehad, A. R., Anastos, H., Wajswol, E., Winoker, J. S., Sfakianos, J. P., Doppalapudi, S. K., Carrick, M. R., Knauer, C. J., Taouli, B., Lewis, S. C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906929116 · Cited by 884
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Croissant, J. G., Fatieiev, Y., & Khashab, N. M. (2017) · Advanced Materials · doi:10.1002/adma.201604634 · Cited by 782
Lactoferrin: a general review.
Levay, P., & Viljoen, M. (1995) · PubMed · Cited by 769
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757
Monocarboxylate transporters in the central nervous system: distribution, regulation and function
Pierre, K., & Pellerin, L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03168.x · Cited by 744
Metal–Organic Framework‐Based Stimuli‐Responsive Systems for Drug Delivery
Cai, W., Wang, J., Chu, C., Chen, W., Wu, C., & Liu, G. (2019) · Advanced Science · doi:10.1002/advs.201801526 · Cited by 744
Glioblastoma survival in the United States before and during the temozolomide era
Johnson, D. R., & O’Neill, B. P. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0749-4 · Cited by 720
Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., & Lejeune, F. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.52 · Cited by 719
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 661
The INTERPHONE Study Group (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyq079 · Cited by 657
Anselmo, A. C., Zhang, M., Kumar, S., Vogus, D. R., Menegatti, S., Helgeson, M. E., & Mitragotri, S. (2015) · ACS Nano · doi:10.1021/acsnano.5b00147 · Cited by 643
Yi, H.-G., Jeong, Y. H., Kim, Y., Choi, Y.-J., Moon, H. E., Park, S. H., Kang, K. S., Bae, M., Jang, J., Youn, H., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0363-x · Cited by 634
Stupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630
Mainprize, T., Lipsman, N., Huang, Y., Meng, Y., Bethune, A., Ironside, S., Heyn, C., Alkins, R., Trudeau, M., Sahgal, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36340-0 · Cited by 618
Ekstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Lan, G., Tang, H., Pelizzari, C., Fu, Y.-X., Spiotto, M. T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0203-4 · Cited by 596
Sugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients
Zeppernick, F., Ahmadi, R., Campos, B., Dictus, C., Helmke, B. M., Becker, N., Lichter, P., Unterberg, A., Radlwimmer, B., & Herold-Mende, C. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0932 · Cited by 588
Shaping Cancer Nanomedicine: The Effect of Particle Shape on The In Vivo Journey of Nanoparticles
Toy, R., Peiris, P. M., Ghaghada, K. B., & Karathanasis, E. (2014) · Nanomedicine · doi:10.2217/nnm.13.191 · Cited by 570
Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches
Cardoso, F. L., Brites, D., & Brito, M. A. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.05.003 · Cited by 569
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Design of Folic Acid‐Conjugated Nanoparticles for Drug Targeting
Stella, B., Arpicco, S., Peracchia, M. T., Desmaële, D., Hoebeke, J., Renoir, M., D'Angelo, J., Cattel, L., & Couvreur, P. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200011)89:11<1452::aid-jps8>3.0.co;2-p · Cited by 553
Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers
Popat, A., Hartono, S. B., Stahr, F., Liu, J., Qiao, S. Z., & Qing (Max) Lu, G. (2011) · Nanoscale · doi:10.1039/c1nr10224a · Cited by 548
Self-citationArnida, Janát-Amsbury, M. M., Ray, A., Peterson, C. M., & Ghandehari, H. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.11.010 · Cited by 547
Kunzmann, A., Andersson, B., Thurnherr, T., Krug, H., Scheynius, A., & Fadeel, B. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.04.007 · Cited by 527
The P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas
Brem, H., Mahaley, M. S., Vick, N. A., Black, K. L., Schold, S. C., Burger, P. C., Friedman, A. H., Ciric, I. S., Eller, T. W., Cozzens, J. W., et al. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.74.3.0441 · Cited by 488
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Epidemiology and Outcome of Glioblastoma
Department of Neurosurgery, J. U. H. A. M. S., TAMIMI, A. F., JUWEID, M., & Department of Radiology and Nuclear Medicine, J. U. H. A. M. S. (2017) · Glioblastoma · doi:10.15586/codon.glioblastoma.2017.ch8 · Cited by 484
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Kunwar, S., Chang, S., Westphal, M., Vogelbaum, M., Sampson, J., Barnett, G., Shaffrey, M., Ram, Z., Piepmeier, J., Prados, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop054 · Cited by 483
Ye, X.-Z., Xu, S.-L., Xin, Y.-H., Yu, S.-C., Ping, Y.-F., Chen, L., Xiao, H.-L., Wang, B., Yi, L., Wang, Q.-L., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103248 · Cited by 477
Izadifar, Z., Izadifar, Z., Chapman, D., & Babyn, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020460 · Cited by 457
Lactoferrin: Multifunctional roles of lactoferrin: a critical overview
Ward, P. P., Paz, E., & Conneely, O. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5369-8 · Cited by 443
First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip
Farra, R., Sheppard, N. F., McCabe, L., Neer, R. M., Anderson, J. M., Santini, J. T., Cima, M. J., & Langer, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003276 · Cited by 437
Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., Bekele, B. N., & Aldape, K. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop020 · Cited by 434
Piao, J.-G., Wang, L., Gao, F., You, Y.-Z., Xiong, Y., & Yang, L. (2014) · ACS Nano · doi:10.1021/nn503779d · Cited by 426
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Ahir, B. K., Engelhard, H. H., & Lakka, S. S. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01892-8 · Cited by 424
Stealth Coating of Nanoparticles in Drug-Delivery Systems
Fam, S. Y., Chee, C. F., Yong, C. Y., Ho, K. L., Mariatulqabtiah, A. R., & Tan, W. S. (2020) · Nanomaterials · doi:10.3390/nano10040787 · Cited by 422
Limitations of stereotactic biopsy in the initial management of gliomas
Jackson, R. J., Fuller, G. N., Abi-Said, D., Lang, F. F., Gokaslan, Z. L., Shi, W. M., Wildrick, D. M., & Sawaya, R. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.3.193 · Cited by 416
Cellular backpacks for macrophage immunotherapy
Shields, C. W., Evans, M. A., Wang, L. L.-W., Baugh, N., Iyer, S., Wu, D., Zhao, Z., Pusuluri, A., Ukidve, A., Pan, D. C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6579 · Cited by 414
Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer
Watermann, A., & Brieger, J. (2017) · Nanomaterials · doi:10.3390/nano7070189 · Cited by 404
The EGFRvIII variant in glioblastoma multiforme
Gan, H. K., Kaye, A. H., & Luwor, R. B. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.12.005 · Cited by 396
Incidence of gliomas by anatomic location
Larjavaara, S., Mäntylä, R., Salminen, T., Haapasalo, H., Raitanen, J., Jääskeläinen, J., & Auvinen, A. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-016 · Cited by 396
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 390
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.139 · Cited by 388
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier
Fillebeen, C., Descamps, L., Dehouck, M.-P., Fenart, L., Benaı̈ssa, M., Spik, G., Cecchelli, R., & Pierce, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7011 · Cited by 385
Cui, Y., Xu, Q., Chow, P. K.-H., Wang, D., & Wang, C.-H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.075 · Cited by 376
Keles, G. E., Anderson, B., & Berger, M. S. (1999) · Surgical Neurology · doi:10.1016/s0090-3019(99)00103-2 · Cited by 366
Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude
Brenner, J. S., Pan, D. C., Myerson, J. W., Marcos-Contreras, O. A., Villa, C. H., Patel, P., Hekierski, H., Chatterjee, S., Tao, J.-Q., Parhiz, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05079-7 · Cited by 363
Idbaih, A., Canney, M., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3643 · Cited by 362
Rai, R., Alwani, S., & Badea, I. (2019) · Polymers · doi:10.3390/polym11040745 · Cited by 350
Immunosuppressive mechanisms in glioblastoma: Fig. 1.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov151 · Cited by 348
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Lidar, Z., Mardor, Y., Jonas, T., Pfeffer, R., Faibel, M., Nass, D., Hadani, M., & Ram, Z. (2004) · Journal of Neurosurgery · doi:10.3171/jns.2004.100.3.0472 · Cited by 342
Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., & Oldfield, E. H. (1995) · Journal of Neurosurgery · doi:10.3171/jns.1995.82.6.1021 · Cited by 341
Mehta, A. M., Sonabend, A. M., & Bruce, J. N. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0520-4 · Cited by 331
Focused ultrasound-mediated drug delivery through the blood–brain barrier
Burgess, A., Shah, K., Hough, O., & Hynynen, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1028369 · Cited by 323
Marko, N. F., Weil, R. J., Schroeder, J. L., Lang, F. F., Suki, D., & Sawaya, R. E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.8886 · Cited by 315
Systemic Review of Biodegradable Nanomaterials in Nanomedicine
Su, S., & Kang, P. M. (2020) · Nanomaterials · doi:10.3390/nano10040656 · Cited by 312
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.050 · Cited by 311
MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.012 · Cited by 307
The significance of artificial intelligence in drug delivery system design
Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.001 · Cited by 305
Gliomas and the vascular fragility of the blood brain barrier
Dubois, L. G., Campanati, L., Righy, C., D’Andrea-Meira, I., Spohr, T. C. L. D. S. E., Porto-Carreiro, I., Pereira, C. M., Balça-Silva, J., Kahn, S. A., DosSantos, M. F., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00418 · Cited by 303
De Palma, M., Mazzieri, R., Politi, L. S., Pucci, F., Zonari, E., Sitia, G., Mazzoleni, S., Moi, D., Venneri, M. A., Indraccolo, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.004 · Cited by 301
Self-citationKuhnt, D., Becker, A., Ganslandt, O., Bauer, M., Buchfelder, M., & Nimsky, C. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor133 · Cited by 300
McGirt, M. J., Than, K. D., Weingart, J. D., Chaichana, K. L., Attenello, F. J., Olivi, A., Laterra, J., Kleinberg, L. R., Grossman, S. A., Brem, H., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.5.17557 · Cited by 299
Johanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C., Chang, E., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 289
Pharmacokinetics of the Carmustine Implant
Fleming, A. B., & Saltzman, W. M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00002 · Cited by 287
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Wang, X., Guo, G., Guan, H., Yu, Y., Lu, J., & Yu, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1085-3 · Cited by 286
Harashima, H., Sakata, K., Funato, K., & Kiwada, H. (1994) · Pharmaceutical Research · doi:10.1023/a:1018965121222 · Cited by 284
Cohen, M. H., Johnson, J. R., & Pazdur, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0722 · Cited by 282
Oberoi, R. K., Parrish, K. E., Sio, T. T., Mittapalli, R. K., Elmquist, W. F., & Sarkaria, J. N. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov164 · Cited by 280
Biodegradable and Renal Clearable Inorganic Nanoparticles
Ehlerding, E. B., Chen, F., & Cai, W. (2016) · Advanced Science · doi:10.1002/advs.201500223 · Cited by 277
Recurrent glioblastoma multiforme: a review of natural history and management options
Hou, L. C., Veeravagu, A., Hsu, A. R., & Tse, V. C. K. (2006) · Neurosurgical Focus · doi:10.3171/foc.2006.20.4.2 · Cited by 275
Grabowski, M. M., Sankey, E. W., Ryan, K. J., Chongsathidkiet, P., Lorrey, S. J., Wilkinson, D. S., & Fecci, P. E. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03483-y · Cited by 270
Das, S., & Marsden, P. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmcibr1309402 · Cited by 268
Souweidane, M. M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S., Zanzonico, P., Carrasquillo, J. A., Lyashchenko, S. K., Thakur, S. B., Donzelli, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30322-x · Cited by 267
Oppenlander, M. E., Wolf, A. B., Snyder, L. A., Bina, R., Wilson, J. R., Coons, S. W., Ashby, L. S., Brachman, D., Nakaji, P., Porter, R. W., et al. (2014) · Journal of Neurosurgery · doi:10.3171/2013.12.jns13184 · Cited by 266
Petrarca, C., Clemente, E., Di Giampaolo, L., Mariani-Costantini, R., Leopold, K., Schindl, R., Lotti, L. V., Mangifesta, R., Sabbioni, E., Niu, Q., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/295092 · Cited by 266
Liu, W., Wang, Z., Zhang, L., Wei, X., & Li, L. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00340.x · Cited by 259
Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R., & Elmquist, W. F. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167601 · Cited by 255
Drug Resistance in Glioblastoma: A Mini Review
Haar, C. P., Hebbar, P., Wallace, G. C., Das, A., Vandergrift, W. A., Smith, J. A., Giglio, P., Patel, S. J., Ray, S. K., & Banik, N. L. (2012) · Neurochemical Research · doi:10.1007/s11064-011-0701-1 · Cited by 254
Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets
Miranda-Gonçalves, V., Honavar, M., Pinheiro, C., Martinho, O., Pires, M. M., Pinheiro, C., Cordeiro, M., Bebiano, G., Costa, P., Palmeirim, I., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos298 · Cited by 252
Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art
Karim, R., Palazzo, C., Evrard, B., & Piel, G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.026 · Cited by 252
Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma
Bastiancich, C., Danhier, P., Préat, V., & Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.034 · Cited by 252
Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma
Voges, J., Reszka, R., Gossmann, A., Dittmar, C., Richter, R., Garlip, G., Kracht, L., Coenen, H. H., Sturm, V., Wienhard, K., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10688 · Cited by 250
Understanding the Lipid and Protein Corona Formation on Different Sized Polymeric Nanoparticles
Lima, T., Bernfur, K., Vilanova, M., & Cedervall, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-57943-6 · Cited by 250
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel, C., Kim, R. B., Kajiji, S. M., Guengerich, P. F., Wilkinson, G. R., & Wood, A. J. J. (1999) · PubMed · Cited by 249
Zhao, P., Wang, Y., Kang, X., Wu, A., Yin, W., Tang, Y., Wang, J., Zhang, M., Duan, Y., & Huang, Y. (2018) · Chemical Science · doi:10.1039/c7sc04853j · Cited by 248
Sloan, A. E., Ahluwalia, M. S., Valerio-Pascua, J., Manjila, S., Torchia, M. G., Jones, S. E., Sunshine, J. L., Phillips, M., Griswold, M. A., Clampitt, M., et al. (2013) · Journal of Neurosurgery · doi:10.3171/2013.1.jns1291 · Cited by 246
Attenello, F. J., Mukherjee, D., Datoo, G., McGirt, M. J., Bohan, E., Weingart, J. D., Olivi, A., Quinones-Hinojosa, A., & Brem, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0048-2 · Cited by 244
Wu, M., Zhang, H., Tie, C., Yan, C., Deng, Z., Wan, Q., Liu, X., Yan, F., & Zheng, H. (2018) · Nature Communications · doi:10.1038/s41467-018-07250-6 · Cited by 242
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
Greish, K., Nehoff, H., Parayath, N., Domanovitch, L., & Taurin, S. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s47129 · Cited by 238
Huang, R., Ke, W., Liu, Y., Jiang, C., & Pei, Y. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.09.024 · Cited by 229
Nanostructured carriers as innovative tools for cancer diagnosis and therapy
Martinelli, C., Pucci, C., & Ciofani, G. (2019) · APL Bioengineering · doi:10.1063/1.5079943 · Cited by 228
The natural history of extracranial metastasis from glioblastoma multiforme
Lun, M., Lok, E., Gautam, S., Wu, E., & Wong, E. T. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0575-8 · Cited by 223
Core–Shell Gold Nanorod@Metal–Organic Framework Nanoprobes for Multimodality Diagnosis of Glioma
Shang, W., Zeng, C., Du, Y., Hui, H., Liang, X., Chi, C., Wang, K., Wang, Z., & Tian, J. (2017) · Advanced Materials · doi:10.1002/adma.201604381 · Cited by 222
Feinberg, B., Kurzrock, R., Talpaz, M., Blick, M., Saks, S., & Gutterman, J. U. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1328 · Cited by 221
Paulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J., & Low, P. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003723 · Cited by 220
Guerrero-Cázares, H., Tzeng, S. Y., Young, N. P., Abutaleb, A. O., Quiñones-Hinojosa, A., & Green, J. J. (2014) · ACS Nano · doi:10.1021/nn501197v · Cited by 220
Rational Design of Cancer Nanomedicine for Simultaneous Stealth Surface and Enhanced Cellular Uptake
Jin, Q., Deng, Y., Chen, X., & Ji, J. (2019) · ACS Nano · doi:10.1021/acsnano.8b07746 · Cited by 219
Leuthardt, E. C., Duan, C., Kim, M. J., Campian, J. L., Kim, A. H., Miller-Thomas, M. M., Shimony, J. S., & Tran, D. D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148613 · Cited by 216
Temozolomide for high grade glioma
Hart, M. G., Garside, R., Rogers, G., Stein, K., & Grant, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007415.pub2 · Cited by 213
Gliadel Wafers in the Treatment of Malignant Glioma: A Systematic Review
Perry, J., Chambers, A., Spithoff, K., Laperriere, N., & on behalf of the Neuro-Oncology Disease Site Group§ of Cancer Care Ontario’s Program in Evidence-Based Care (2007) · Current Oncology · doi:10.3747/co.2007.147 · Cited by 212
The renaissance of interferon therapy for the treatment of myeloid malignancies
Kiladjian, J.-J., Mesa, R. A., & Hoffman, R. (2011) · Blood · doi:10.1182/blood-2010-08-258772 · Cited by 212
Size, shape, and flexibility influence nanoparticle transport across brain endothelium under flow
Nowak, M., Brown, T. D., Graham, A., Helgeson, M. E., & Mitragotri, S. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10153 · Cited by 211
Lamano, J. B., Lamano, J. B., Li, Y. D., DiDomenico, J. D., Choy, W., Veliceasa, D., Oyon, D. E., Fakurnejad, S., Ampie, L., Kesavabhotla, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2402 · Cited by 209
Zeng, W., Tang, Z., Li, Y., Yin, G., Liu, Z., Gao, J., Chen, Y., & Chen, F. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1086-5 · Cited by 208
The Evidence of Glioblastoma Heterogeneity
Soeda, A., Hara, A., Kunisada, T., Yoshimura, S.-I., Iwama, T., & Park, D. M. (2015) · Scientific Reports · doi:10.1038/srep07979 · Cited by 205
Oncolytic Virus Therapy for Glioblastoma Multiforme: Concepts and Candidates
Wollmann, G., Ozduman, K., & van den Pol, A. N. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824671c9 · Cited by 205
Nanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204
Alzheimer's disease drug development and the problem of the blood‐brain barrier
Pardridge, W. M. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.06.003 · Cited by 203
Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy
Li, W., Liu, Z., Fontana, F., Ding, Y., Liu, D., Hirvonen, J. T., & Santos, H. A. (2018) · Advanced Materials · doi:10.1002/adma.201703740 · Cited by 200
Rock, K., Mcardle, O., Forde, P., Dunne, M., Fitzpatrick, D., O'Neill, B., & Faul, C. (2012) · The British Journal of Radiology · doi:10.1259/bjr/83796755 · Cited by 199
Threatening cancer with nanoparticle aided combination oncotherapy
Rawal, S., & Patel, M. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.015 · Cited by 199
Van Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J.-S., Franceschi, E., Clement, P. M., Chinot, O., De Vos, F., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 198
Debayle, M., Balloul, E., Dembele, F., Xu, X., Hanafi, M., Ribot, F., Monzel, C., Coppey, M., Fragola, A., Dahan, M., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119357 · Cited by 196
Ashby, L. S., Smith, K. A., & Stea, B. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0975-5 · Cited by 192
Brown, T. D., Habibi, N., Wu, D., Lahann, J., & Mitragotri, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00743 · Cited by 182
Budhwani, M., Mazzieri, R., & Dolcetti, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00322 · Cited by 181
Self-citationPD-L1/PD-1 Axis in Glioblastoma Multiforme
Litak, J., Mazurek, M., Grochowski, C., Kamieniak, P., & Roliński, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215347 · Cited by 180
Sun, Z., Wang, L., Wu, S., Pan, Y., Dong, Y., Zhu, S., Yang, J., Yin, Y., & Li, G. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05241 · Cited by 180
Li, J., Zhao, J., Tan, T., Liu, M., Zeng, Z., Zeng, Y., Zhang, L., Fu, C., Chen, D., & Xie, T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s243223 · Cited by 178
Nasab, N. A., Kumleh, H. H., Beygzadeh, M., Teimourian, S., & Kazemzad, M. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1290648 · Cited by 177
Hamidi, H. (2019) · Future Generation Computer Systems · doi:10.1016/j.future.2018.09.024 · Cited by 175
Widera, A., Norouziyan, F., & Shen, W.-C. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.07.004 · Cited by 173
Wen, P. Y., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 171
Chowdhary, S. A., Ryken, T., & Newton, H. B. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1724-2 · Cited by 167
Glioblastoma: Therapeutic challenges, what lies ahead
Lima, F. R. S., Kahn, S. A., Soletti, R. C., Biasoli, D., Alves, T. R., da Fonseca, A. C. C., Garcia, C., Romão, L. F., Brito, J. M., Afonso, R. C. D. H., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.05.004 · Cited by 163
Farrell, C. J., & Plotkin, S. R. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.008 · Cited by 162
Ultrasound-mediated drug delivery to the brain: principles, progress and prospects
Dasgupta, A., Liu, M., Ojha, T., Storm, G., Kiessling, F. M., & Lammers, T. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.07.007 · Cited by 162
Multifunctional porous silicon nanoparticles for cancer theranostics
Wang, C.-F., Sarparanta, M. P., Mäkilä, E. M., Hyvönen, M. L. K., Laakkonen, P. M., Salonen, J. J., Hirvonen, J. T., Airaksinen, A. J., & Santos, H. A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.008 · Cited by 160
Recurrence Pattern Analysis of Primary Glioblastoma
Rapp, M., Baernreuther, J., Turowski, B., Steiger, H., Sabel, M., & Kamp, M. A. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.04.053 · Cited by 160
Mo, J., He, L., Ma, B., & Chen, T. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b11730 · Cited by 159
Rapid transferrin efflux from brain to blood across the blood–brain barrier
Zhang, Y., & Pardridge, W. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00222.x · Cited by 159
Mobile phone use and brain tumours in the CERENAT case-control study
Coureau, G., Bouvier, G., Lebailly, P., Fabbro-Peray, P., Gruber, A., Leffondre, K., Guillamo, J.-S., Loiseau, H., Mathoulin-Pélissier, S., Salamon, R., et al. (2014) · Occupational and Environmental Medicine · doi:10.1136/oemed-2013-101754 · Cited by 159
Van Woensel, M., Wauthoz, N., Rosière, R., Amighi, K., Mathieu, V., Lefranc, F., Van Gool, S., & De Vleeschouwer, S. (2013) · Cancers · doi:10.3390/cancers5031020 · Cited by 158
Towards understanding of nanoparticle–protein corona
Ge, C., Tian, J., Zhao, Y., Chen, C., Zhou, R., & Chai, Z. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1458-0 · Cited by 158
Aryal, M., Fischer, K., Gentile, C., Gitto, S., Zhang, Y.-Z., & McDannold, N. (2017) · PLOS ONE · doi:10.1371/journal.pone.0166061 · Cited by 158
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Chen, C., Jing, W., Chen, Y., Wang, G., Abdalla, M., Gao, L., Han, M., Shi, C., Li, A., Sun, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1128 · Cited by 291
Janjua, T. I., Cao, Y., Kleitz, F., Linden, M., Yu, C., & Popat, A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115115 · Cited by 259
Self-citationLiu, X., Cao, Z., Wang, W., Zou, C., Wang, Y., Pan, L., Jia, B., Zhang, K., Zhang, W., Li, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12857 · Cited by 132
Metadata
- Authors
- Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., & Popat, A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 171
- Pages
- 108-138
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3124899091
- Cited by
- 257
- References
- 403
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.